Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015', provides an overview of the Genital Warts (Condylomata Acuminata)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Genital Warts (Condylomata Acuminata) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Genital Warts (Condylomata Acuminata) Overview 8
Therapeutics Development 9
Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 9
Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 10
Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Genital Warts (Condylomata Acuminata) - Products under Development by Companies 14
Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 15
Agilvax, Inc. 15
Biogenomics Limited 16
BioMAS Ltd. 17
Biota Pharmaceuticals, Inc. 18
Foamix Pharmaceuticals Ltd. 19
G&E Herbal Biotechnology Co., Ltd. 20
Helix BioPharma Corp. 21
Laboratories Ojer Pharma S.L. 22
LEO Pharma A/S 23
MediGene AG 24
NanoViricides, Inc. 25
Novan, Inc. 26
Novartis AG 27
Tamir Biotechnology, Inc. 28
Zydus Cadila Healthcare Limited 29
Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AS-101 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AX-03 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BTA-074 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Herpecide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
imiquimod - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
imiquimod SR - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ingenol mebutate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
interferon alfa-2b - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
interferon alpha-2b (recombinant) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LFX-453 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NVN-1000 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PP-210 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ranpirnase - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SB-206 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
sinecatechins - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SRT-100 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Vaccine for Cervical Cancer and Genital Warts - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates 65
Genital Warts (Condylomata Acuminata) - Dormant Projects 70
Genital Warts (Condylomata Acuminata) - Discontinued Products 71
Genital Warts (Condylomata Acuminata) - Product Development Milestones 72
Featured News & Press Releases 72
Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries 72
Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries 72
Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen 72
Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland 73
Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen® in United Kingdom and Ireland 73
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 73
Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia 74
Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan 74
Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada 75
Jul 29, 2013: Medigene: Market launch of Veregen in the Netherlands started 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2015 15
Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H2 2015 16
Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2015 17
Genital Warts (Condylomata Acuminata) - Pipeline by Biota Pharmaceuticals, Inc., H2 2015 18
Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 19
Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015 20
Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H2 2015 21
Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H2 2015 22
Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H2 2015 23
Genital Warts (Condylomata Acuminata) - Pipeline by MediGene AG, H2 2015 24
Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H2 2015 25
Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H2 2015 26
Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H2 2015 27
Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H2 2015 28
Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 29
Assessment by Monotherapy Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H2 2015 65
Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2015 70
Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2015 71